BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wu MN, Zheng WJ, Ye WX, Wang L, Chen Y, Yang J, Yao DF, Yao M. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth. World J Gastroenterol 2021; 27(23): 3327-3341 [PMID: 34163115 DOI: 10.3748/wjg.v27.i23.3327]
URL: https://www.wjgnet.com/1007-9327/full/v27/i23/3327.htm
Number Citing Articles
1
Nabil M. Abdel‐Hamid, Sherin M. Zakaria, Abeer M. Ansary, Fardous F. El‐Senduny, Mamdouh M. El‐Shishtawy. The expression of tuftelin 1 as a new theranostic marker in early diagnosis and as a therapeutic target in hepatocellular carcinomaCell Biochemistry and Function 2023; 41(7): 788 doi: 10.1002/cbf.3828
2
Jing Chen, Sheng Wu, Jue Wang, Yu Sha, Yong Ji. Hsa_circ_0074269-mediated Upregulation of TUFT1 Through miR-485-5p Increases Cisplatin Resistance in Cervical CancerReproductive Sciences 2022; 29(8): 2236 doi: 10.1007/s43032-022-00855-9
3
Lei Zhu, Kai X. Zhou, Ming Z. Ma, Lin L. Yao, Yan L. Zhang, Hui Li, Chang Du, Xiao M. Yang, Lingzhang Meng. Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion MaturationJournal of Immunology Research 2022; 2022: 1 doi: 10.1155/2022/1590717
4
Artur Słomka, Miroslaw Kornek, William C. Cho. Small Extracellular Vesicles and Their Involvement in Cancer Resistance: An Up-to-Date ReviewCells 2022; 11(18): 2913 doi: 10.3390/cells11182913